# Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

> **NCT00649272** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Oxybutynin Chloride Extended-Release Tablets, 15 mg
- **DRUG:** Ditropan XL® Extended-release tablets, 15 mg

## Key facts

- **NCT ID:** NCT00649272
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649272, "Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00649272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*